Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 26 of 32.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    EudraCT Number: 2017-002634-24 Sponsor Protocol Number: MultipleMS Start Date*: 2017-09-29
    Sponsor Name:Karolinska Institutet
    Full Title: MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients.
    Medical condition: Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004505-32 Sponsor Protocol Number: COMB157G3301 Start Date*: 2021-06-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choi...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000910-40 Sponsor Protocol Number: PHRC-N/2012/ET-01 Start Date*: 2013-04-12
    Sponsor Name:CHU de Nîmes
    Full Title: Étude multicentrique, randomisée en double aveugle versus placebo évaluant l’efficacité d’un traitement par Cholécalciférol (Vitamine D3) pour retarder la conversion en SEP après un syndrome cliniq...
    Medical condition: Les patients âgés de 18 à 50 ans ayant présenté depuis moins de 60 jours un SCI typique (NORB, myélite, syndrome du tronc cérébral ou sus-tentoriel) avec présence à l’IRM cérébro-médullaire de plus...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10028247 Multiple sclerosis like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021978-11 Sponsor Protocol Number: 101MS326 Start Date*: 2011-05-04
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
    Medical condition: Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) FI (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) ES (Completed) PL (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004719-10 Sponsor Protocol Number: AC-058B303 Start Date*: 2017-10-02
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Completed) PL (Completed) CZ (Completed) BG (Completed) LV (Completed) HU (Completed) LT (Completed) PT (Completed) HR (Completed) GB (GB - no longer in EU/EEA) FI (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-000254-11 Sponsor Protocol Number: 33375 Start Date*: 2014-03-28
    Sponsor Name:Department of Neurology
    Full Title: ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
    Medical condition: Mulple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002333-19 Sponsor Protocol Number: OMS112831 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10070716 Multiple sclerosis pseudo relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000028-36 Sponsor Protocol Number: P3-IMU-838-RMS-01 Start Date*: 2022-04-21
    Sponsor Name:Immunic AG
    Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000770-60 Sponsor Protocol Number: CFTY720DIT03 Start Date*: 2011-04-12
    Sponsor Name:NOVARTIS FARMA
    Full Title: “An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists”
    Medical condition: approximately 600 patients with relapsing-remitting MS for whom no suitable therapy exists i.e. where existing therapies have failed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001031-63 Sponsor Protocol Number: AV650-018 Start Date*: 2007-09-20
    Sponsor Name:Avigen Inc
    Full Title: AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects...
    Medical condition: Spasticity associated with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028335 Muscle spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004412-11 Sponsor Protocol Number: CBX-001 Start Date*: 2015-01-16
    Sponsor Name:Canbex Therapeutics Ltd
    Full Title: A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects wi...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005548-17 Sponsor Protocol Number: 69HCL14-0438 Start Date*: 2015-04-28
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY
    Medical condition: PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10029864 Nystagmus PT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000721-31 Sponsor Protocol Number: RIDOSE-MS Start Date*: 2018-07-04
    Sponsor Name:Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
    Full Title: RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term ...
    Medical condition: Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002509-63 Sponsor Protocol Number: GWCL0403 Start Date*: 2005-03-11
    Sponsor Name:GW Pharma Ltd
    Full Title: A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    Medical condition: Spasticity due to Multiple Sclerosis (MS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003498-41 Sponsor Protocol Number: D-Fampr Start Date*: 2015-09-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of dalfampridine on mobility in the context of daily life
    Medical condition: Motor behaviour and cognition in multiple sclerosis patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001776-13 Sponsor Protocol Number: 2005-MS-LEV-1 Start Date*: 2005-08-05
    Sponsor Name:Organisation name was not entered
    Full Title: Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002916-28 Sponsor Protocol Number: EMR200166-001 Start Date*: 2013-12-12
    Sponsor Name:Merck KGaA
    Full Title: An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-002062-62 Sponsor Protocol Number: ALS-TAL-201 Start Date*: 2008-10-14
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral S...
    Medical condition: Amyotrophic lateral sclerosis (ALS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) ES (Completed) IT (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 15:07:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA